ClinicalTrials.gg
RecruitingNCT06248333STEMUpdated Jul 15, 2025

Subthalamic Nucleus Electrical Stimulation for Drug-resistant Focal Motor Epilepsy

An interventional study of STN-DBS ON and STN-DBS OFF in Epilepsy, Drug Resistant, sponsored by Xuanwu Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 14 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-07-15.

Sponsored by Xuanwu Hospital, Beijing · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
14 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing — 11 open to participants now, 12 under way, none of them phase 3. Drug Resistant Epilepsy · Xuanwu Hospital, Beijing.

Planned enrollment
Largest of 12
33 · median 13
Started
2024
with 11 others
No phase
10 of 15
7 open now
Primary completion
2025-12
later than 3 of 11 live
Registered
1st of 15
by date

Among the 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing, this one has the largest planned enrollment of the 12 interventional ones that give a count, is one of 12 that started in 2024, is one of 10 with no phase, reaches primary completion later than 3 of the 11 other live ones, and was the 1st registered.

Drug Resistant Epilepsy

258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.

Browse Drug Resistant Epilepsy studies →

Open to participants now

11 of the 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 68 Drug Resistant Epilepsy studies recruiting now, 27 (40%) set no upper age limit and 40 (59%) stop at 75 or younger; 27 take children under 18; 6 take healthy volunteers.

This study: 14 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing, or all of them as a file.
02

Study summary

The primary objective of this research is to study the efficacy and safety of deep brain stimulation (DBS) of subthalamic nucleus (STN) as adjunctive therapy for reducing the frequency of seizures in drug-resistant focal motor epilepsy.

Read the detailed description

This is a multicenter, randomized, double-blind, sham-controlled, parallel-group trial that aims to investigate the efficacy of STN-DBS in reducing the frequency of seizures in drug-resistant focal motor epilepsy. Participants who were eligible for the inclusion criteria and ineligible for the exclusion criteria will be randomly assigned into two groups by a 1:1 ratio. The primary purpose of this study is to compare active STN-DBS with sham STN-DBS in reducing seizure frequency. Both intent analysis (ITT) and compliance program set (PPS) were used for analysis. Only high-volume centers with a proven track record will be included. The STEM trial will be conducted in 5 sites in China.

03

Conditions studied

  • Epilepsy, Drug Resistant

Keywords

  • Deep Brain Stimulation
  • Drug Resistant Epilepsy
  • Subthalamic Nucleus
  • Focal Motor Epilepsy
04

Who can participate

Ages eligible
14 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 14-65 years of age, inclusive, at Screening Visit.
  • to anti-seizure medications (ASMs).
  • Diagnosed with focal motor epilepsy, which meets the following items:

    1. Seizure mainly presents as focal tonic, myoclonic, or primary motor seizure (including primary sensory seizure), with or without secondary bilateral tonic-clonic seizure.
    2. After a comprehensive evaluation, the epileptogenic zone was presumed to predominantly involve the unilateral or bilateral central area (precentral gyrus, postcentral gyrus, and paracentral lobule) or supplementary motor area according to comprehensive presurgical evaluation.
  • Within 1 month prior to the Screening Visit (M-3), the following conditions are met:

    1. At least 3 focal onset seizures (with or without secondary bilateral tonic-clonic seizure).
    2. Subject is receiving at least one type of ASM[s], and the regimen has been stable (no addition or removal of ASM[s] [not counting brief rescue medicines such as benzodiazepines]; dose adjustments are permitted to ASM[s]).
  • Within the baseline period (3 months after the Screening Visit [M-3]), the following conditions are met:

    1. The patient or their caregiver is capable of completing the seizure diary.
    2. Seizure diary shows an average of 3 or more partial-onset seizures (with or without secondary bilateral tonic-clonic seizure) per month during the Baseline Period, with no more than 30 days between seizures.
    3. The regimen of ASM[s] has been stable (no addition or removal of ASM[s] [not counting brief rescue medicines such as benzodiazepines]; dose adjustments are permitted to ASM[s]).
  • After comprehensive preoperative evaluation, patients who are considered unsuitable for or refuse resection surgery, or those for whom the effects of epileptic focus resection and thermocoagulation surgery are not satisfactory.
  • signed.

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with generalized or hereditary epilepsy with ion channel gene mutations;
  • Seizures mainly present as complex motor seizures (e.g., hyperkinetic, automatisms, etc.);
  • Tonic-clonic status epilepticus within12 months;
  • Psychogenic non-epileptic seizures within 12 months;
  • Structural lesion of the subthalamic nucleus;
  • Presence of implanted electrical stimulation medical device anywhere in the body (e.g., pacemaker, spinal cord stimulator, responsive neurostimulation) or any metallic implants in the head (e.g., aneurysm clips, cochlear implants). Note: Vagal nerve stimulators are allowed if the parameter remains stable for at least 3 months prior to the screening visit;
  • Risk factors that would put the participant at risk for intraoperative or postoperative bleeding. (e.g., coagulation abnormalities, etc.) or the need for chronic anticoagulation or antiplatelet aggregation medications;
  • IQ \< 55 or severe cognitive dysfunction, unable to complete the study;
  • Diagnosed with a progressive neurological disorder (including progressive Rasmussen's encephalitis, etc.);
  • Diagnosed with a severe neuropsychiatric disorder such as dementia, major depression (admission to a psychiatric specialty/hospital within 5 years or any suicidal or self-injurious tendencies), schizophrenia, or neurodegenerative disorders;
  • Diagnosed with other serious physical disorders, internal diseases or severe abnormalities in liver or kidney function;
  • Pregnant, or planning to pregnant within 2 years;
  • Participation in another clinical study within 3 months;
  • Not suitable for enrollment as assessed by the multidisciplinary team of the center.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    Active Stimulation

    After randomization, participants will undergo STN-DBS ON in the 3-month blinded phase (Month 2 to Month 5) with the individual stimulation parameters determined in the parameter determination period, then continue to receive stimulation for the remainder of the study.

    Device: STN-DBS ON

  • Sham comparator
    Sham Stimulation

    After randomization, participants will undergo STN-DBS OFF in the 3-month blinded phase (Month 2 to Month 5) with 0mA current, then the stimulator will be turned on with individual stimulation parameters and left on for the remainder of the study.

    Device: STN-DBS OFF

Interventions

  • DeviceSTN-DBS ON

    Stimulation ON

  • DeviceSTN-DBS OFF

    Stimulation OFF

06

What researchers measure

Primary outcomes

  1. Median Percent Change in Seizure Frequency

    Seizure frequency (SF28) is defined as seizure count per month (28-day) period. The SF28 is calculated as follows, where D=total number of days for which seizure information is collected for the specific 28-day interval: SF28=(Total number of seizures in D days/D)\*28. In addition, the baseline seizure frequency is defined as mean of 3-month SF28 in the baseline period. The seizure frequency in double-blind phase is defined as SF28 per month during the double-blind period. Percent change in seizure frequency=100\*(double-blind SF28-baseline SF28)/baseline SF28.

    Time frame: Through the end of the three-month blinded phase

Secondary outcomes

  1. Seizure Responder Rate

    The proportion of patients with a ≥ 50% reduction from Baseline in seizure frequency.

    Time frame: Through the end of the three-month blinded phase

  2. Seizure Severity

    The percent change from baseline in seizure severity evaluated by Liverpool seizure severity scale (LSSS) across the double-blind period.

    Time frame: Through the end of the three-month blinded phase

  3. Seizure-free Days

    Change in percentage of seizure-free days over the entire blinded phase as compared to the entire baseline phase. The number of seizure-free days was normalized to 84-day baseline and blinded phases for each subject.

    Time frame: Through the end of the three-month blinded phase

  4. The maximum length of seizure-free Intervals

    Percentage change in the maximum length of seizure-free intervals over the entire blinded phase as compared to the entire baseline phase.

    Time frame: Through the end of the three-month blinded phase

  5. Life quality evaluation

    Percentage change from baseline in Quality of Life in Epilepsy-31 inventory (QOLIE-31) score at 3 months after randomization.

    Time frame: Through the end of the three-month blinded phase

  6. Motor function evaluation

    Percentage change from baseline in Unified Parkinson's Disease Rating Scale part II \& part III (UPDRS II-III) score at 3 months after randomization.

    Time frame: Through the end of the three-month blinded phase

  7. Cognitive function evaluation (MMSE)

    Percentage change from baseline in Mini-Mental State Examination (MMSE) score at 3 months after randomization.

    Time frame: Through the end of the three-month blinded phase

  8. Cognitive function evaluation (MoCA)

    Percentage change from baseline in Montreal Cognitive Assessment (MoCA) score at 3 months after randomization.

    Time frame: Through the end of the three-month blinded phase

  9. Psychologic Evaluation (Anxiety)

    Percentage change from baseline in Hamilton Anxiety Rating Scale (HAMA) score at 3 months after randomization.

    Time frame: Through the end of the three-month blinded phase

  10. Psychologic Evaluation (Depression)

    Percentage change from baseline in Hamilton Depression Rating Scale (HAMD) score at 3 months after randomization.

    Time frame: Through the end of the three-month blinded phase

  11. Sleep Quality

    Percentage change from baseline in Pittsburgh Sleep Quality Index (PSQI) score at 3 months after randomization.

    Time frame: Through the end of the three-month blinded phase

  12. Adverse Events

    Rate of adverse events which were judged to be study-related throughout the study.

    Time frame: Through Month 11 of the open-label follow-up phase

  13. Incidence of Sudden Unexpected Death in Epilepsy (SUDEP)

    The number presented is for Definite and Probable SUDEP. The rate is calculated per 1000 subject years of follow-up.

    Time frame: Through Month 11 of the open-label follow-up phase

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2025, 22 months after the start.

Of 90 non-industry interventional studies with no phase under Drug Resistant Epilepsy, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21. This study's planned 22 months is below that.

Counting every sponsor, half of 102 studies reached it within 34 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2024
First posted
Feb 8, 2024
StartActual
Feb 14, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Jun 30, 2026
Last update
Jul 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06248333
Responsible party
Liankun_Ren (Professor, Xuanwu Hospital, Beijing) — Principal investigator
First posted
Feb 8, 2024
Start date
Feb 14, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Jul 15, 2025

Study contacts

Liankun Ren, MD
Contact
renlk2022@outlook.com
+86 13681576621
Liankun Ren, MD
principal investigator · Xuanwu Hospital, Beijing

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion